Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Proffered Paper - Translational research

1189O - Validation of whole genome sequencing in routine clinical practice


19 Sep 2020


Proffered Paper - Translational research


Clinical Research;  Pathology/Molecular Biology;  Basic Science;  Translational Research

Tumour Site


Kim Monkhorst


Annals of Oncology (2020) 31 (suppl_4): S725-S734. 10.1016/annonc/annonc262


K. Monkhorst1, K. Samsom1, L. Schipper2, P. Roepman3, L. Bosch4, E. de Bruijn3, L.R. Hoes2, I. Riethorst3, L. Schoenmaker3, L. van der Kolk5, T. Buffart6, K. van der Hoeven3, E.E. Voest7, E. Cuppen3, G. Meijer8

Author affiliations

  • 1 Pathology Department, NKI-AVL - Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, 1066 CX - Amsterdam/NL
  • 2 Molecular Oncology Dept., NKI-AVL - Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, 1066 CX - Amsterdam/NL
  • 3 Medical Department, Hartwig Medical Foundation, 1098XH - Amsterdam/NL
  • 4 Translational Gastrointestinal Oncology, Netherlands Cancer Institute, 1066CX - Amsterdam/NL
  • 5 Family Cancer Clinic, NKI-AVL - Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, 1066 CX - Amsterdam/NL
  • 6 Gastrointestinal Oncology, NKI-AVL - Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, 1066 CX - Amsterdam/NL
  • 7 Molecular Oncology, Netherlands Cancer Institute/Antoni van Leeuwenhoek hospital (NKI-AVL), 1066 CX - Amsterdam/NL
  • 8 Pathology Dept, NKI-AVL - Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, 1066 CX - Amsterdam/NL


Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 1189O


Clinical-grade Whole Genome Sequencing (cWGS) is currently being implemented in routine practice. In the WIDE study (WGS Implementation in standard cancer Diagnostics for Every cancer patient), cWGS is performed on a prospective cohort of 1,200 patients (stage IV solid tumors). Here we report the results on feasibility and clinical validity (primary endpoints) of the first 600 patients.


cWGS was conducted independently of, but in parallel with, validated Standard-of-Care (SOC) diagnostics. For 47% of patients, this included SOC molecular diagnostics (MolDx). cWGS and MolDx results were compared and discussed in a dedicated tumor board. Initial discordances were further evaluated by additional tests.


cWGS was successfully performed in 69% (414/602) of patients with a technical success rate of 96% (414/433). Ineligibility for cWGS was mostly caused by an insufficient number of tumor cells (<20%) in the received biopsy (86%, 145/169). MolDx was performed in 47% (283/602) and was successful in 95% (267/283) of patients. cWGS showed a median turn-around-time (TAT) of 14 days, which decreased incrementally by continuous improvements to the clinical procedure and cWGS pipeline. In total, 480 genomic biomarkers for clinical validation were identified by SOC MolDx. cWGS showed an error rate of 4.2% (20/480) compared to a SOC MolDx error rate of 1% (5/480). Most of the biomarkers that were not reported by cWGS (19 of 20) were present in the raw data but not reliably identified due to very low variant allele frequencies. Improvements to further increase the sensitivity are currently being implemented with an anticipated reduction of the cWGS error rate to 2%. Overall, cWGS identified a clinically actionable (routine practice and experimental) biomarker in 74% of all patients tested. Compared to SOC MolDx, cWGS identified one or more additional treatment options in 69% (197/287) of patients. Interestingly, in patients that were not tested by SOC MolDx, actionable variants were identified in 60% (76/126).


Based on the first 600 patients of the WIDE study, cWGS was found to be clinically feasible in routine molecular diagnostics in a comprehensive cancer center setting and has added value by providing additional treatment options for the majority of patients.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

Gerrit Meijer, Emile Voest and Kim Monkhorst.


The Netherlands Organisation for Health Research and Care innovation (ZonMW) and Hartwig Medical Foundation.


K. Monkhorst: Honoraria (self), Advisory/Consultancy, Research grant/Funding (self), Travel/Accommodation/Expenses: F. Hoffmann-La Roche; Honoraria (self), Advisory/Consultancy, Research grant/Funding (self): AstraZeneca; Research grant/Funding (self): PDGx; Honoraria (self), Advisory/Consultancy, Travel/Accommodation/Expenses: MSD; Advisory/Consultancy: Pfizer; Advisory/Consultancy: BMS; Advisory/Consultancy: Abbvie; Advisory/Consultancy: Diaceutics; Travel/Accommodation/Expenses: Takeda. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.